Effect of Viratarvadi Kwath with Shuddh Shilajeet over Varunadi Kwath with Gokshuradi Guggulu, among patients who are on standard care in management of Mutraghata (~Chronic Kidney Disease up to Grade 3b), an Open-label, Randomized Comparative Clinical Trial

A Randomized Open-Label Comparative Clinical Trial Evaluating the Efficacy of Viratarvadi Kwath with Shuddha Shilajeet versus Varunadi Kwath with Gokshuradi Guggulu as Add-on Therapy in the Management of Mutraghata (Chronic Kidney Disease up to Grade3b) - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105159

Enrollment

Registered

2026-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients of all genders. Patients diagnosed with signs and symptoms of chronic kidney disease as per standard KDIGO criteria of known etiology, including diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, or hereditary causes such as autosomal dominant polycystic kidney disease ADPKD shall be included. Patient presenting with symptoms of Mutraghata. The NAMASTE Portal, having serial no. 1258, the morbidity code EJ 3, corresponds to Mutraghata. Patients of the age group 21 to 65 yrs. with confirmed diagnosis of stage up to G3B as per standard KDIGO CRITERIA, eGFR greater than 30 ml per min. per 1.73 m and less than 60 ml per min. per 1.73 square meters not having undergone RRT were included. Subjects who are willing to sign the informed written consent. Subjects who are not registered in any other research project in the last 12 weeks.

Exclusion criteria

Exclusion criteria: 1.HIV-associated nephropathy and transplant allograph failure 2.Renal Artery stenosis. 3.Neoplasm of Kidney. 4.History of previous kidney transplant. 5.Patients of Congenital Renal Diseases like Autosomal dominant and Recessive Polycystic Kidney disease, Congenital Nephrotic syndrome (Finnish type), Alport s syndrome, Fabry,s disease and juvenile Nephronophthisis. 6.Patients with clinically diagnosed cardiorenal syndromes, including those with congestive heart failure, ischemic heart disease with reduced ejection fraction ,or acute or chronic cardiac conditions significantly contributing to renal dysfunction, shall be excluded from the study. 7.Uncontrolled diabetes HbA1C greater than 9 percentage and uncontrolled HTN greater than 160/100mmHg. 8.Patients suffering from Tuberculosis, Malignancy, Pregnancy and lactation, or any other systemic illness.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of Viratarvadi Kwath with Shuddh Shilajeet over Varunadi Kwath with Gokshuradi Guggulu in the management of Mutraghataa (Chronic Kidney Disease up to grade 3B) based on Improvement in the Serum Creatinine, eGFR , Hb levels and Urine albuminTimepoint: 4 weeks	—

Secondary

Measure	Time frame
1)Improving Serum Urea, BUN level, and Serum Electrolytes level.Timepoint: 4 weeks;2)Improving classical signs and symptoms of Mutravaha Stroto Dushti 1).Atishrita-atibaddam-Alpo-alp mutra Bahal mutra 2.Shwaskricchta 3.Raktalpata-Pandutvam 4.Aksikut-mukha-pada Shavyathu 5)Dhatukashya Timepoint: 4 weeks;3)Improving Quality of Life (Kidney Disease and Quality of Life -KDQOL-36).Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactMuskan Goyal

All India Institute of Ayurveda

muskangoel1908@gmail.com7838329627

Outcome results